The Impact of Chemotherapy after Pediatric Malignancy on Humoral Immunity to Vaccine-Preventable Diseases.
Chemotherapy
Pediatric malignancy
Vaccination
Journal
Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
11
2019
accepted:
09
02
2020
entrez:
18
3
2020
pubmed:
18
3
2020
medline:
18
3
2020
Statut:
epublish
Résumé
The antibody titer of vaccine-preventable diseases in pediatric patients who underwent chemotherapy was assessed in order to evaluate the seroprotection after treatment and the feasibility and the efficacy of a policy of revaccination. Serum antibody titers of 55 patients for hepatitis B (HBV), rubella, varicella-zoster (VZV), measles, mumps, polio viruses, We confirm that seroprotection for vaccine-preventable diseases is affected by treatment for pediatric malignancy. A single booster dose of vaccine might be a practical way to restore vaccine immunity in patients after chemotherapy.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The antibody titer of vaccine-preventable diseases in pediatric patients who underwent chemotherapy was assessed in order to evaluate the seroprotection after treatment and the feasibility and the efficacy of a policy of revaccination.
METHODS
METHODS
Serum antibody titers of 55 patients for hepatitis B (HBV), rubella, varicella-zoster (VZV), measles, mumps, polio viruses,
CONCLUSIONS
CONCLUSIONS
We confirm that seroprotection for vaccine-preventable diseases is affected by treatment for pediatric malignancy. A single booster dose of vaccine might be a practical way to restore vaccine immunity in patients after chemotherapy.
Identifiants
pubmed: 32180909
doi: 10.4084/MJHID.2020.014
pii: mjhid-12-1-e2020014
pmc: PMC7059740
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2020014Déclaration de conflit d'intérêts
Competing interests: The authors declare no conflict of Interest.
Références
Ann Saudi Med. 2011 Nov-Dec;31(6):573-6
pubmed: 22048500
J Transl Med. 2017 Jul 10;15(1):155
pubmed: 28693586
Lancet Infect Dis. 2019 Jun;19(6):e188-e199
pubmed: 30744964
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S195-203
pubmed: 20042227
Cancer. 2004 Aug 1;101(3):635-41
pubmed: 15274078
Pediatr Blood Cancer. 2014 Nov;61(11):2077-9
pubmed: 24789692
Lancet Infect Dis. 2019 Jun;19(6):e200-e212
pubmed: 30744963
Arthritis Care Res (Hoboken). 2014 Jul;66(7):1016-26
pubmed: 24339395
Hematol Oncol. 2016 Sep;34(3):121-32
pubmed: 27402426
Pediatr Blood Cancer. 2005 May;44(5):461-8
pubmed: 15558707
Eur J Pediatr. 2017 Sep;176(9):1269-1273
pubmed: 28730317
J Korean Med Sci. 2012 Jan;27(1):78-83
pubmed: 22219618
Br J Haematol. 2007 Jun;137(5):457-60
pubmed: 17488489
Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238
pubmed: 19747629
MMWR Morb Mortal Wkly Rep. 1999 Apr 2;48(12):241-3
pubmed: 10220250
Vaccine. 2014 Jun 5;32(27):3357-61
pubmed: 24793952
Euro Surveill. 2017 Sep 14;22(37):
pubmed: 28933342
Blood. 2002 Sep 15;100(6):2257-9
pubmed: 12200395
J Pediatr Hematol Oncol. 2018 Mar;40(2):e99-e102
pubmed: 29309372
Leukemia. 2006 Oct;20(10):1717-22
pubmed: 16888619